Aspire Biopharma Holdings Inc. is an early-stage biopharmaceutical company focused on developing and marketing disruptive sublingual delivery technology for drugs and supplements. This patent-pending platform enables rapid absorption directly into the bloodstream through tissues under the tongue, bypassing the gastrointestinal tract to enhance bioavailability, speed of onset, and reduce side effects like gastrointestinal irritation. The company's lead product, Instaprin, is a soluble, pH-neutral, fast-acting sublingual aspirin powder designed for cardiology emergencies and pain management. Aspire Biopharma Holdings Inc. applies its technology across a pipeline of reformulated pharmaceuticals, including melatonin sleep aids, vitamins D, E, and K, testosterone, semaglutide, anti-nausea, anti-psychotic, erectile dysfunction, seizure medications, and others. In the consumer space, it commercializes BUZZ BOMB, a sublingual caffeine supplement in flavors like Tropical Fruit and Mixed Berry, offered through its subsidiary Buzz Bomb Caffeine Company LC for quick energy and cognitive support. Founded in 2021 and headquartered in Estero, Florida, Aspire Biopharma Holdings Inc. operates in the biotechnology sector, targeting improved drug delivery for emergency and everyday health applications.